Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Clinical trial NCT07153965 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07153965
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer (TNBC)PD-L1 Positive

Start date: 2025-09-01
Primary completion: 2026-09-01
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.